See more : Trigano S.A. (TRI.PA) Income Statement Analysis – Financial Results
Complete financial analysis of IRIDEX Corporation (IRIX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of IRIDEX Corporation, a leading company in the Medical – Devices industry within the Healthcare sector.
- Thai Beverage Public Company Limited (Y92.SI) Income Statement Analysis – Financial Results
- SES-imagotag Société Anonyme (SESL.PA) Income Statement Analysis – Financial Results
- Eucrates Biomedical Acquisition Corp. (EUCRU) Income Statement Analysis – Financial Results
- Al Mal Capital PSC – Al Mal Capital REIT (AMCREIT.AE) Income Statement Analysis – Financial Results
- Ruida Futures Co., Ltd. (002961.SZ) Income Statement Analysis – Financial Results
IRIDEX Corporation (IRIX)
About IRIDEX Corporation
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 51.87M | 56.97M | 53.90M | 36.35M | 43.45M | 42.60M | 41.59M | 46.16M | 41.76M | 42.81M | 38.27M | 33.86M | 33.16M | 43.69M | 43.21M | 48.53M | 55.53M | 35.90M | 37.03M | 32.81M | 31.70M | 30.63M | 27.28M | 33.44M | 26.76M | 23.60M | 18.10M | 12.40M | 8.80M |
| Cost of Revenue | 30.06M | 31.60M | 31.07M | 20.79M | 25.51M | 25.13M | 26.09M | 25.32M | 21.80M | 21.41M | 19.69M | 17.51M | 16.87M | 22.79M | 22.94M | 28.85M | 31.25M | 17.10M | 18.85M | 17.92M | 17.63M | 17.05M | 14.21M | 13.75M | 10.97M | 9.60M | 7.20M | 4.70M | 2.70M |
| Gross Profit | 21.81M | 25.37M | 22.83M | 15.56M | 17.94M | 17.47M | 15.50M | 20.84M | 19.95M | 21.41M | 18.59M | 16.35M | 16.29M | 20.90M | 20.27M | 19.68M | 24.28M | 18.81M | 18.18M | 14.89M | 14.07M | 13.59M | 13.07M | 19.69M | 15.79M | 14.00M | 10.90M | 7.70M | 6.10M |
| Gross Profit Ratio | 42.04% | 44.53% | 42.36% | 42.80% | 41.29% | 41.01% | 37.27% | 45.15% | 47.78% | 50.00% | 48.56% | 48.28% | 49.13% | 47.84% | 46.92% | 40.55% | 43.73% | 52.38% | 49.08% | 45.38% | 44.39% | 44.36% | 47.92% | 58.89% | 59.01% | 59.32% | 60.22% | 62.10% | 69.32% |
| Research & Development | 6.83M | 7.18M | 6.87M | 3.28M | 3.68M | 4.01M | 5.73M | 5.37M | 5.21M | 4.63M | 3.68M | 4.39M | 3.91M | 3.81M | 3.61M | 4.01M | 5.78M | 5.51M | 4.20M | 4.51M | 4.03M | 4.32M | 4.81M | 5.27M | 3.93M | 3.10M | 1.70M | 1.30M | 0.00 |
| General & Administrative | 8.75M | 7.56M | 8.86M | 6.62M | 8.38M | 9.55M | 8.26M | 7.64M | 5.55M | 6.03M | 5.02M | 4.93M | 4.26M | 4.49M | 4.87M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 16.24M | 18.18M | 14.64M | 12.24M | 14.85M | 16.78M | 14.54M | 10.28M | 8.90M | 8.16M | 7.72M | 7.90M | 7.46M | 9.80M | 9.27M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 24.99M | 25.74M | 23.50M | 18.86M | 23.23M | 26.33M | 22.80M | 17.92M | 14.45M | 14.19M | 12.74M | 12.82M | 11.72M | 14.29M | 14.15M | 17.84M | 27.93M | 18.06M | 12.17M | 11.46M | 10.09M | 9.45M | 10.25M | 10.75M | 9.22M | 8.40M | 6.10M | 5.20M | 4.60M |
| Other Expenses | 0.00 | 60.00K | 2.35M | 280.00K | 209.00K | 92.00K | -107.00K | -91.00K | 3.00K | -1.26M | -371.00K | -210.00K | 0.00 | 0.00 | 0.00 | 5.36M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 31.81M | 32.91M | 30.36M | 22.14M | 26.91M | 30.34M | 28.53M | 23.28M | 19.67M | 18.82M | 15.95M | 17.21M | 14.36M | 18.11M | 17.76M | 21.85M | 48.40M | 23.57M | 16.37M | 15.96M | 14.12M | 13.77M | 15.06M | 16.91M | 13.97M | 12.20M | 8.20M | 6.70M | 4.70M |
| Cost & Expenses | 61.88M | 64.51M | 61.44M | 42.93M | 52.42M | 55.47M | 54.62M | 48.60M | 41.47M | 40.23M | 35.64M | 34.72M | 31.23M | 40.90M | 40.69M | 50.70M | 79.65M | 40.67M | 35.22M | 33.89M | 31.75M | 30.82M | 29.26M | 30.65M | 24.94M | 21.80M | 15.40M | 11.40M | 7.40M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 733.00K | 528.00K | 249.00K | 159.00K | 151.00K | 378.00K | 552.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.26M | 371.00K | 210.00K | 296.00K | 78.00K | 237.00K | 507.00K | 644.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.03M | 1.38M | 803.00K | 504.00K | 688.00K | 809.00K | 858.00K | 648.00K | 522.00K | 420.00K | 490.00K | 427.00K | 410.00K | 515.00K | 899.00K | 3.22M | 3.82M | 542.00K | 435.00K | 384.00K | 703.00K | 869.00K | 859.00K | 893.00K | 817.00K | 700.00K | 400.00K | 200.00K | 100.00K |
| EBITDA | -7.98M | -6.10M | -6.73M | -6.08M | -8.29M | -12.06M | -12.17M | -1.80M | 810.00K | 3.01M | 2.65M | 267.00K | 2.85M | 4.11M | 4.22M | -3.52M | -17.80M | -3.49M | 2.24M | -373.00K | 655.00K | 688.00K | -1.13M | 3.21M | 2.29M | 2.47M | 3.03M | 1.20M | 1.50M |
| EBITDA Ratio | -15.38% | -13.24% | -13.98% | -18.11% | -20.66% | -30.21% | -31.66% | -5.04% | 0.69% | 6.04% | 6.88% | -4.90% | 7.07% | 7.58% | 5.83% | 2.16% | -14.60% | -11.76% | 6.06% | -2.32% | 1.90% | 2.34% | -4.32% | 10.95% | 9.55% | 8.47% | 13.81% | 4.03% | 15.91% |
| Operating Income | -10.01M | -7.54M | -7.53M | -6.58M | -8.97M | -12.87M | -12.89M | -2.57M | 288.00K | 2.59M | 2.63M | -860.00K | 1.93M | 2.80M | 2.52M | -7.54M | -24.12M | -4.77M | 1.81M | -1.08M | -48.00K | -181.00K | -1.99M | 2.79M | 1.83M | 1.80M | 2.70M | 1.00M | 1.40M |
| Operating Income Ratio | -19.29% | -13.24% | -13.98% | -18.11% | -20.66% | -30.21% | -30.99% | -5.56% | 0.69% | 6.04% | 6.88% | -2.54% | 5.83% | 6.40% | 5.83% | -15.53% | -43.43% | -13.27% | 4.89% | -3.28% | -0.15% | -0.59% | -7.29% | 8.34% | 6.82% | 7.63% | 14.92% | 8.06% | 15.91% |
| Total Other Income/Expenses | 527.00K | 60.00K | 2.35M | 280.00K | 209.00K | 92.00K | -107.00K | -91.00K | 3.00K | -1.26M | -371.00K | -110.00K | 504.00K | 722.00K | 563.00K | 293.00K | 1.86M | 733.00K | 528.00K | 319.00K | 212.00K | 122.00K | 426.00K | 569.00K | 556.00K | 500.00K | 600.00K | 700.00K | 100.00K |
| Income Before Tax | -9.48M | -7.48M | -5.19M | -6.30M | -8.77M | -12.78M | -13.00M | -2.66M | 291.00K | 1.33M | 2.26M | -270.00K | 2.44M | 3.52M | 3.08M | -7.24M | -22.26M | -4.03M | 2.34M | -757.00K | 164.00K | -59.00K | -1.56M | 3.36M | 2.38M | 2.30M | 3.30M | 1.70M | 1.50M |
| Income Before Tax Ratio | -18.28% | -13.13% | -9.62% | -17.34% | -20.17% | -29.99% | -31.24% | -5.75% | 0.70% | 3.11% | 5.91% | -0.80% | 7.35% | 8.05% | 7.13% | -14.93% | -40.08% | -11.23% | 6.31% | -2.31% | 0.52% | -0.19% | -5.73% | 10.04% | 8.90% | 9.75% | 18.23% | 13.71% | 17.05% |
| Income Tax Expense | 90.00K | 65.00K | 40.00K | 26.00K | 48.00K | 37.00K | -128.00K | 9.06M | -183.00K | -8.71M | 31.00K | -100.00K | 297.00K | 473.00K | 496.00K | 127.00K | 13.00K | 1.72M | 666.00K | -355.00K | -207.00K | -209.00K | -962.00K | 940.00K | 763.00K | 600.00K | 1.20M | 700.00K | 500.00K |
| Net Income | -9.57M | -7.55M | -5.23M | -6.33M | -8.81M | -12.81M | -12.87M | -11.71M | 474.00K | 10.04M | 2.23M | 1.44M | 2.61M | 3.05M | 2.59M | -7.37M | -22.27M | -5.75M | 1.67M | -402.00K | 371.00K | 150.00K | -1.27M | 2.42M | 1.62M | 1.70M | 2.10M | 1.00M | 1.00M |
| Net Income Ratio | -18.45% | -13.25% | -9.69% | -17.41% | -20.28% | -30.08% | -30.94% | -25.38% | 1.14% | 23.45% | 5.83% | 4.25% | 7.87% | 6.97% | 5.98% | -15.19% | -40.11% | -16.02% | 4.51% | -1.23% | 1.17% | 0.49% | -4.67% | 7.23% | 6.05% | 7.20% | 11.60% | 8.06% | 11.36% |
| EPS | -0.59 | -0.47 | -0.34 | -0.46 | -0.64 | -1.05 | -1.11 | -1.15 | 0.05 | 1.01 | 0.24 | 0.16 | 0.29 | 0.34 | 0.29 | -0.84 | -2.69 | -0.75 | 0.23 | -0.06 | 0.05 | 0.02 | -0.19 | 0.36 | 0.25 | 0.27 | 0.33 | 0.16 | 0.78 |
| EPS Diluted | -0.59 | -0.47 | -0.34 | -0.46 | -0.64 | -1.05 | -1.11 | -1.15 | 0.05 | 0.97 | 0.22 | 0.16 | 0.26 | 0.30 | 0.29 | -0.84 | -2.69 | -0.75 | 0.21 | -0.06 | 0.05 | 0.02 | -0.19 | 0.33 | 0.24 | 0.26 | 0.31 | 0.16 | 0.23 |
| Weighted Avg Shares Out | 16.13M | 15.94M | 15.42M | 13.84M | 13.71M | 12.20M | 11.56M | 10.17M | 9.96M | 9.89M | 9.25M | 8.50M | 8.96M | 8.94M | 8.84M | 8.82M | 8.29M | 7.71M | 7.41M | 7.20M | 7.42M | 6.87M | 6.76M | 6.64M | 6.50M | 6.48M | 6.41M | 6.25M | 4.29M |
| Weighted Avg Shares Out (Dil) | 16.13M | 15.94M | 15.42M | 13.84M | 13.71M | 12.20M | 11.56M | 10.17M | 10.13M | 10.36M | 10.10M | 8.94M | 10.23M | 10.13M | 8.94M | 8.82M | 8.29M | 7.71M | 7.88M | 7.20M | 7.42M | 6.93M | 6.76M | 7.29M | 6.85M | 6.77M | 6.76M | 6.25M | 4.29M |
Iridex's Strategic Review Process Should Bear Fruit 'Soon'
IRIDEX Corporation (IRIX) Q4 2023 Earnings Call Transcript
Iridex (IRIX) Reports Q4 Loss, Lags Revenue Estimates
Iridex Reports Fourth Quarter and Full Year 2023 Financial Results
Iridex Schedules Fourth Quarter and Full Year 2023 Financial Results and Update on Strategic Review Process for March 26, 2024
3 Laser Systems Stocks to Watch in a Challenging Industry
Iridex Announces First Patient Enrollment in MicroPulse® TLT Clinical Study Conducted in Collaboration with Imperial College Healthcare NHS Trust
Iridex Launches New Iridex 532® and Iridex 577® Lasers in US Market Marking 35 Years of Laser Innovation in Treating Retina Disorders & Glaucoma
Iridex Confirms Medicare Administrative Contractors Retired Local Coverage Determinations that Restricted Cyclophotocoagulation
Iridex Corporation Announces Successful Appeal for Revision of Recent Medicare LCDs to Provide Broader Coverage of Cyclophotocoagulation
Source: https://incomestatements.info
Category: Stock Reports